Active Biotech AB Total Liabilities
Active Biotech AB total liabilities. Based on the latest financial reports, Active Biotech AB (ACTI) has total liabilities worth Skr10.70 Million SEK (≈ $1.15 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Active Biotech AB (ACTI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Active Biotech AB (2000–2025)
Total liabilities of Active Biotech AB from 2000 to 2025. This chart illustrates how Active Biotech AB's total liabilities have evolved over time, based on quarterly financial data.
Active Biotech AB Competitors by Total Liabilities
The table below lists competitors of Active Biotech AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chuan Huat Resources Bhd
KLSE:7016
|
Malaysia | RM319.65 Million |
|
aXichem AB
ST:AXIC-A
|
Sweden | Skr9.69 Million |
|
Kingfish Company Nv
OL:KING
|
Norway | Nkr122.14 Million |
|
Netlinkz Ltd
AU:NET
|
Australia | AU$28.13 Million |
|
NPK Co.Ltd
KQ:048830
|
Korea | ₩23.33 Billion |
|
Imugene Ltd
AU:IMU
|
Australia | AU$25.80 Million |
|
HANHUA FNCL HLDG CO.H YC1
F:5HF
|
Germany | €5.03 Billion |
|
Huize Holding Ltd
NASDAQ:HUIZ
|
USA | $506.32 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Active Biotech AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Active Biotech AB asset portfolio.
Liquidity & Leverage Metrics
Active Biotech AB Total Liabilities Ratios Explained
Active Biotech AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Active Biotech AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Active Biotech AB (2000–2025)
The table below shows the annual total liabilities of Active Biotech AB from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr14.60 Million ≈ $1.57 Million |
+31.18% |
| 2024-12-31 | Skr11.13 Million ≈ $1.20 Million |
-16.82% |
| 2023-12-31 | Skr13.38 Million ≈ $1.44 Million |
-18.88% |
| 2022-12-31 | Skr16.49 Million ≈ $1.78 Million |
+62.82% |
| 2021-12-31 | Skr10.13 Million ≈ $1.09 Million |
+0.88% |
| 2020-12-31 | Skr10.04 Million ≈ $1.08 Million |
-23.76% |
| 2019-12-31 | Skr13.17 Million ≈ $1.42 Million |
-93.86% |
| 2018-12-31 | Skr214.52 Million ≈ $23.09 Million |
-5.14% |
| 2017-12-31 | Skr226.14 Million ≈ $24.34 Million |
-1.82% |
| 2016-12-31 | Skr230.32 Million ≈ $24.79 Million |
-14.33% |
| 2015-12-31 | Skr268.84 Million ≈ $28.93 Million |
-15.25% |
| 2014-12-31 | Skr317.21 Million ≈ $34.14 Million |
-12.47% |
| 2013-12-31 | Skr362.40 Million ≈ $39.00 Million |
+1.56% |
| 2012-12-31 | Skr356.82 Million ≈ $38.40 Million |
+0.08% |
| 2011-12-31 | Skr356.53 Million ≈ $38.37 Million |
+10.95% |
| 2010-12-31 | Skr321.34 Million ≈ $34.58 Million |
+3.70% |
| 2009-12-31 | Skr309.86 Million ≈ $33.35 Million |
+0.17% |
| 2008-12-31 | Skr309.34 Million ≈ $33.29 Million |
+3.12% |
| 2007-12-31 | Skr299.97 Million ≈ $32.28 Million |
-25.39% |
| 2006-12-31 | Skr402.04 Million ≈ $43.27 Million |
+2.81% |
| 2005-12-31 | Skr391.05 Million ≈ $42.08 Million |
+159.68% |
| 2004-12-31 | Skr150.59 Million ≈ $16.21 Million |
+169.76% |
| 2003-12-31 | Skr55.82 Million ≈ $6.01 Million |
-36.01% |
| 2002-12-31 | Skr87.24 Million ≈ $9.39 Million |
+26.51% |
| 2001-12-31 | Skr68.96 Million ≈ $7.42 Million |
-69.07% |
| 2000-12-31 | Skr222.92 Million ≈ $23.99 Million |
-- |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye disea… Read more